As part of our ongoing aim to bring you reports of new developments, we have added a short review of the ASPIRE study: carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. This is the first of three new short studies which will be published over the next month.
Independent commentary is provided by Associate Professor Cindy Lee, the clinical co-lead in the myeloma program at Royal Adelaide Hospital and The Queen Elizabeth Hospital, South Australia.
Please login below to download this issue (PDF)